Drug Profile
IONIS GSK4LRx
Alternative Names: IONISGSK4LRx; ISIS-GSK4-LRx; ISIS-GSK4RxLatest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer GSK
- Class Antisense oligonucleotides; Eye disorder therapies
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for phase-I development in Eye-disorders(In volunteers) in United Kingdom
- 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
- 26 Oct 2015 Phase-I clinical trials in Eye disorders (In volunteers) in United Kingdom (unspecified route)